HOUSTON (December 1, 2021) – T3 Advisors, A Savills Company, today announced the opportunity to acquire the fee simple interest of a biomanufacturing facility located at 8800 Health Science Center Parkway in Bryan, Texas.

iBio, a developer of next-generation biopharmaceuticals, is seeking a forward-thinking landlord or developer to obtain ownership in its newly acquired and globally recognized manufacturing facility in the rapidly growing Texas Research Triangle, equidistant from Austin, Dallas, and Houston. The company purchased the facility it previously operated under a lease in November.

In total, the site encompasses 36 acres, including iBio’s two-story, 139,000-square-foot manufacturing facility. The facility was commissioned in 2011 and is one of the largest plant-producing and cGMP-approved biologics facilities in the world. Additionally, the site is prime for expansion, with 15 acres available for ground-up development and the option to further extend iBio’s facility by 125,000 to 175,000 square feet.

Savills Executive Vice President and Head of Life Sciences, Austin Barrett, Executive Vice President Mark Cote, Senior Managing Director Lindsay Stroud and Managing Director Allison Hoffman will oversee the strategy and sale process for iBio. Corporate Managing Director RJ Panzo and Managing Director Tim Maynes will oversee lab and facility planning as the company evaluates its scientific needs.

“It is no secret that investment in the Texas Research Triangle has been robust with more than $400 million in funding secured by life sciences companies since 2018. As we understand this sector on the most granular levels, we are well-positioned to advise iBio on identifying an ideal partner that shares in the company’s long-term vision. We are expecting significant demand for this centrally located facility,” said Barrett.

Earlier this month, the Savills team kicked off the iBio engagement by procuring the $22,375,000 debt package, allowing iBio to purchase the facility for $28,750,000. The acquisition enabled iBio to reduce carrying costs by 67%, providing the company with the opportunity to invest capital in expanding its workforce in Texas as well as driving further expansion of its pioneering FastPharming System.